Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock

Patients with cardiogenic shock were assigned to receive milrinone or dobutamine for inotropic support. There was no significant difference between the two groups in the composite primary outcome of in-hospital death from any cause or cardiovascular or renal events.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-08, Vol.385 (6), p.516-525
Hauptverfasser:	Mathew, Rebecca, Di Santo, Pietro, Jung, Richard G, Marbach, Jeffrey A, Hutson, Jordan, Simard, Trevor, Ramirez, F. Daniel, Harnett, David T, Merdad, Anas, Almufleh, Aws, Weng, Willy, Abdel-Razek, Omar, Fernando, Shannon M, Kyeremanteng, Kwadwo, Bernick, Jordan, Wells, George A, Chan, Vincent, Froeschl, Michael, Labinaz, Marino, Le May, Michel R, Russo, Juan J, Hibbert, Benjamin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Agonists - therapeutic use Aged Cardiology Cardiotonic Agents - adverse effects Cardiotonic Agents - therapeutic use Cerebral infarction Clinical trials Comorbidity Confidence intervals Consent Critical Care Dobutamine - adverse effects Dobutamine - therapeutic use Double-Blind Method Emergency Medicine Female General & Internal Medicine Heart attacks Heart Failure Heart transplantation Hospital Mortality Humans Hypertension Ischemia Length of stay Life Sciences & Biomedicine Male Medicine, General & Internal Middle Aged Milrinone - adverse effects Milrinone - therapeutic use Morbidity Myocardial infarction Patients Phosphodiesterase 3 Inhibitors - therapeutic use Pulmonary Science & Technology Sensitivity analysis Shock Shock, Cardiogenic - drug therapy Shock, Cardiogenic - mortality Statistical analysis Transient ischemic attack
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with cardiogenic shock were assigned to receive milrinone or dobutamine for inotropic support. There was no significant difference between the two groups in the composite primary outcome of in-hospital death from any cause or cardiovascular or renal events.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2026845